Full Press Release Details
dupixent dupilumab phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis eoe.
REGN
dupixent dupilumab phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis eoe
Key Takeaway: dupixent dupilumab phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis eoe